Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis
A Phase 2a, Open Label, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Teplizumab in Adults With Moderate or More Severe Psoriasis
Sponsor: Eli Lilly and Company
Terminated
Injection site reaction met protocol-defined stopping criteria.
This PHASE1/PHASE2 trial investigates Psoriasis and is currently terminated or withdrawn. Eli Lilly and Company leads this study, which shows 12 recorded versions since 2009 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE1_PHASE2
▶ Show 7 earlier versions
-
Mar 2022 — Dec 2022 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2022 — Mar 2022 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Dec 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
- MacroGenics
For direct contact, visit the study record on ClinicalTrials.gov .